首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >Mining Data From Plasma Cell Differentiation Identified Novel Genes for Engineering of a Yeast Antibody Factory
【24h】

Mining Data From Plasma Cell Differentiation Identified Novel Genes for Engineering of a Yeast Antibody Factory

机译:来自血浆细胞分化的挖掘数据确定了一种用于酵母抗体厂工程的新基因

获取原文
           

摘要

Saccharomyces cerevisiae is a common platform for production of therapeutic proteins, but it is not intrinsically suited for the manufacturing of antibodies. Antibodies are naturally produced by plasma cells and studies conducted on plasma cell differentiation provide a comprehensive blueprint for the cellular transformations needed to create an antibody factory. In this study we mined transcriptomics data from plasma cell differentiation to improve antibody production by S. cerevisiae. Through data exploration, we identified several new target genes. We tested the effects of 14 genetic modifications belonging to different cellular processes on protein production. Four of the tested genes resulted in improved antibody expression. The ER stress sensor IRE1 increased the final titer by 1.8-fold and smaller effects were observed with PSA1, GOT1 and HUT1 increasing antibody titers by 1.6-, 1.4- and 1.4-fold. When testing combinations of these genes, the highest increases were observed when co-expressing IRE1 with PSA1, or IRE1 with PSA1 and HUT1, resulting in 3.8-fold and 3.1-fold higher antibody titers. In contrast, strains expressing IRE1 alone or in combination with the other genes produced similar or lower levels of recombinantly expressed yeast acid phosphatase compared to the controls. Using a genetic UPR responsive GFP reporter construct, we show that IRE1 acts through constitutive activation of the unfolded protein response. Moreover, the positive effect of IRE1 expression was transferable to other antibody molecules. We demonstrate how data exploration from an evolutionary distant, but highly specialized cell type can pinpoint new genetic targets and provide a novel concept for rationalized cell engineering.
机译:Saccharomyces Cerevisiae是一种用于生产治疗性蛋白质的常见平台,但它没有本质上适用于制造抗体。通过血浆细胞天然产生抗体,并且对血浆细胞分化进行的研究提供了制造抗体工厂所需的细胞转化的综合蓝图。在这项研究中,我们从血浆细胞分化中挖掘转录组族数据,以改善S.Cerevisiae的抗体产量。通过数据探索,我们确定了几个新的目标基因。我们测试了14种遗传修饰属于不同细胞过程的蛋白质生产的效果。四个测试基因导致改善的抗体表达。 ER应激传感器IRE1将最终滴度增加1.8倍,用PSA1,GOT1和HUT1增加抗体滴度,观察到较小的效果1.6-,1.4-和1.4倍。当测试这些基因的组合时,当用PSA1和HUT1与PSA1和HUT1共同表达IS1或IS1时,观察到最高的增加,导致3.8倍和3.1倍的抗体滴度。相反,与对照相比,单独表达IS1的菌株或与其他基因组合的菌株产生类似或更低的重组表达酵母酸性磷酸酶。使用遗传uPR响应性GFP报告器构建体,我们表明IS1通过展开蛋白质反应的组成型激活作用。此外,IS1表达的正效应可转移到其他抗体分子。我们展示了如何从进化远处的数据探索,但高度专业化的细胞类型可以针对新的遗传目标来定位新的遗传目标,并为合理化细胞工程提供新颖的概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号